Argenx, an international biotechnology company focused on
autoimmune diseases and cancer, continues to demonstrate a strong commitment to its strategic opportunities towards
2025 and beyond. The firm has been granted approval for
VYVGART Hytrulo, an aid for
chronic inflammatory demyelinating polyneuropathy (CIDP) in China, marking a pivotal point in combating the disease. Additionally, Argenx’s stock price target was raised to
$717 by H.C. Wainwright, with robust growth driving the stock to all-time highs. Several analysts value Argenx's growth potential, seeing the company poised to exceed its "Vision 2030" projections, with Barclays and Jefferies confidently positive after successful trials. Furthermore, Argenx expanded its
global collaboration and license agreement with
Halozyme Therapeutics for the development of its ENHANZE® technology. Financial results for Q3, Q2, Q1 2024 show strong sales growth despite strategic challenges, with Argenx's CEO, Tim Van Hauwermeiren, confident of continuing success, especially with VYVGART's ongoing performance against rivals.
argenx News Analytics from Wed, 28 Feb 2024 08:00:00 GMT to Thu, 06 Feb 2025 11:33:30 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -5
